Literature DB >> 19885231

Intra-individual variability of the metabolic effect of a novel rapid-acting insulin (VIAject) in comparison to regular human insulin.

Marcus Hompesch1, Laura McManus, Roderike Pohl, Patrick Simms, Andreas Pfützner, Elena Bülow, Frank Flacke, Lutz Heinemann, Solomon S Steiner.   

Abstract

BACKGROUND: The variability of the metabolic action of insulin after subcutaneous (sc) injection hampers optimal insulin therapy. Insulin formulations with a reduced tendency to form hexamers might exhibit a reduced variability of absorption from the sc insulin depot into the blood stream.
METHODS: We investigated the within-subject variability of pharmacodynamic and pharmacokinetic properties of an ultra-fast insulin (UFI) formulation and regular human insulin (RHI) in patients with type 1 diabetes. Fourteen patients participated in six 10-hour euglycemic glucose clamp experiments. In this double-blind, crossover study, subjects were randomly assigned to a sequence of two experimental blocks: each block consisted of three doses of 0.1 IU/kg UFI or RHI, respectively, administered on separate days by abdominal sc injection.
RESULTS: Ultra-fast insulin has an earlier onset of action and shorter time to maximal plasma insulin concentration when compared to RHI (tGIR(max) 99 +/- 36 min vs. 154 +/- 74 min, p = 0.002; tC(max) 33 +/- 16 min vs. 97 +/- 39 min, p = 0.00001). The within-subject variability of plasma insulin tC(max) (p = 0.027) and of tGIR(max) (p = 0.022) was less for UFI than for RHI.
CONCLUSIONS: In patients with type 1 diabetes, this UFI showed reduced within-subject variability when compared with RHI.

Entities:  

Keywords:  Viaject; human insulin; insulin therapy; prandial insulin; rapid-acting insulin analogs; variability

Year:  2008        PMID: 19885231      PMCID: PMC2769777          DOI: 10.1177/193229680800200406

Source DB:  PubMed          Journal:  J Diabetes Sci Technol        ISSN: 1932-2968


  3 in total

1.  Comparison of the time-action profiles of U40- and U100-regular human insulin and the rapid-acting insulin analogue B28 Asp.

Authors:  L Heinemann; C Weyer; K Rave; O Stiefelhagen; M Rauhaus; T Heise
Journal:  Exp Clin Endocrinol Diabetes       Date:  1997       Impact factor: 2.949

2.  Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes.

Authors:  Tim Heise; Leszek Nosek; Birgitte Biilmann Rønn; Lars Endahl; Lutz Heinemann; Christoph Kapitza; Eberhard Draeger
Journal:  Diabetes       Date:  2004-06       Impact factor: 9.461

3.  A novel insulin formulation with a more rapid onset of action.

Authors:  S Steiner; M Hompesch; R Pohl; P Simms; F Flacke; T Mohr; A Pfützner; L Heinemann
Journal:  Diabetologia       Date:  2008-07-19       Impact factor: 10.122

  3 in total
  8 in total

1.  Insulin analogs for the treatment of diabetes mellitus: therapeutic applications of protein engineering.

Authors:  Daniel F Berenson; Allison R Weiss; Zhu-Li Wan; Michael A Weiss
Journal:  Ann N Y Acad Sci       Date:  2012-03-13       Impact factor: 5.691

2.  Reduction of postprandial glycemic excursions in patients with type 1 diabetes: a novel human insulin formulation versus a rapid-acting insulin analog and regular human insulin.

Authors:  Lutz Heinemann; Marcus Hompesch; Frank Flacke; Patrick Simms; Rody Pohl; Kerstin Albus; Andreas Pfützner; Solomon Steiner
Journal:  J Diabetes Sci Technol       Date:  2011-05-01

3.  Pharmacokinetics and postprandial glycemic excursions following insulin lispro delivered by intradermal microneedle or subcutaneous infusion.

Authors:  Elaine McVey; Laurence Hirsch; Diane E Sutter; Christoph Kapitza; Sibylle Dellweg; Janina Clair; Kerstin Rebrin; Kevin Judge; Ronald J Pettis
Journal:  J Diabetes Sci Technol       Date:  2012-07-01

4.  Insulin therapies: Current and future trends at dawn.

Authors:  Subhashini Yaturu
Journal:  World J Diabetes       Date:  2013-02-15

Review 5.  Design of non-standard insulin analogs for the treatment of diabetes mellitus.

Authors:  V Pandyarajan; M A Weiss
Journal:  Curr Diab Rep       Date:  2012-12       Impact factor: 4.810

6.  Ultra-rapid absorption of recombinant human insulin induced by zinc chelation and surface charge masking.

Authors:  Roderike Pohl; Robert Hauser; Ming Li; Errol De Souza; Robert Feldstein; Richard Seibert; Koray Ozhan; Nandini Kashyap; Solomon Steiner
Journal:  J Diabetes Sci Technol       Date:  2012-07-01

Review 7.  A review of a family of ultra-rapid-acting insulins: formulation development.

Authors:  Alan Krasner; Roderike Pohl; Patrick Simms; Philip Pichotta; Robert Hauser; Errol De Souza
Journal:  J Diabetes Sci Technol       Date:  2012-07-01

Review 8.  Ultrafast-acting insulins: state of the art.

Authors:  Lutz Heinemann; Douglas B Muchmore
Journal:  J Diabetes Sci Technol       Date:  2012-07-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.